MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
-Treatment of advanced RCC in a patient with liver and bone metastasis
KEYTRUDA (pembrolizumab) RCC /
Products /
Root /

Treatment of advanced RCC in a patient with liver and bone metastasis

Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland) [External links]

Poor risk

Case study summary

Prof. Tom Powles, Clinical Professor of Genitourinary Oncology at Barts Cancer Centre presents a case study of a 45 year old male with advanced Renal Cell Carcinoma, treated with KEYTRUDA® (pembrolizumab) in combination with axitinib. 6 months post nephrectomy for G3 T2 advanced RCC, the patient presented with bone and liver metastases, as well as raised platelets and anaemia.

Poor
45
Male
1
Nil of note (marathon runner)

Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland) [External links]

Length: 02:06

Back to the case study hub →

Supporting documentation

Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-RCC-00253 | Date of Preparation: November 2020